Chemotherapy of non-Hodgkin's lymphomas

Gianni Bonadonna, Silvio Monfardini

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Single agent and combination chemotherapy of non-Hodgkin's lymphomas are reviewed. Cyclophosphamide, vincristine and adriamycin appear to be the most effective single agents. Bleomycin is also effective and particularly indicated either in combination or in patients with active disease and concomitant myelosuppression. Corticosteroids are mostly active in lymphocytic lymphoma. Nitrosourea derivatives appear to be only moderately effective compared to other agents. There are a number of active combinations presently on study, but none can yet be recognized as the treatment of choice for all histologic types. Available data show that cyclic combination chemotherapy produces a higher percentage of complete remissions compared to single agents. This also applies to median duration of response and median survival time. Treatment of non-Hodgkin's lymphomas has improved during the past few years primarily because of intensive cyclic combination chemotherapy and new effective agents. There is a need for an entirely new approach which should be based on standardized histopathologic and staging classification as well as on controlled studies.

Original languageEnglish
Pages (from-to)167-181
Number of pages15
JournalCancer Treatment Reviews
Volume1
Issue number3
DOIs
Publication statusPublished - 1974

Fingerprint

Combination Drug Therapy
Non-Hodgkin's Lymphoma
Drug Therapy
Bleomycin
Vincristine
B-Cell Chronic Lymphocytic Leukemia
Doxorubicin
Cyclophosphamide
Adrenal Cortex Hormones
Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Chemotherapy of non-Hodgkin's lymphomas. / Bonadonna, Gianni; Monfardini, Silvio.

In: Cancer Treatment Reviews, Vol. 1, No. 3, 1974, p. 167-181.

Research output: Contribution to journalArticle

Bonadonna, Gianni ; Monfardini, Silvio. / Chemotherapy of non-Hodgkin's lymphomas. In: Cancer Treatment Reviews. 1974 ; Vol. 1, No. 3. pp. 167-181.
@article{36769bf5ed1642a68a6f01d67db0ce34,
title = "Chemotherapy of non-Hodgkin's lymphomas",
abstract = "Single agent and combination chemotherapy of non-Hodgkin's lymphomas are reviewed. Cyclophosphamide, vincristine and adriamycin appear to be the most effective single agents. Bleomycin is also effective and particularly indicated either in combination or in patients with active disease and concomitant myelosuppression. Corticosteroids are mostly active in lymphocytic lymphoma. Nitrosourea derivatives appear to be only moderately effective compared to other agents. There are a number of active combinations presently on study, but none can yet be recognized as the treatment of choice for all histologic types. Available data show that cyclic combination chemotherapy produces a higher percentage of complete remissions compared to single agents. This also applies to median duration of response and median survival time. Treatment of non-Hodgkin's lymphomas has improved during the past few years primarily because of intensive cyclic combination chemotherapy and new effective agents. There is a need for an entirely new approach which should be based on standardized histopathologic and staging classification as well as on controlled studies.",
author = "Gianni Bonadonna and Silvio Monfardini",
year = "1974",
doi = "10.1016/S0305-7372(74)80001-0",
language = "English",
volume = "1",
pages = "167--181",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Chemotherapy of non-Hodgkin's lymphomas

AU - Bonadonna, Gianni

AU - Monfardini, Silvio

PY - 1974

Y1 - 1974

N2 - Single agent and combination chemotherapy of non-Hodgkin's lymphomas are reviewed. Cyclophosphamide, vincristine and adriamycin appear to be the most effective single agents. Bleomycin is also effective and particularly indicated either in combination or in patients with active disease and concomitant myelosuppression. Corticosteroids are mostly active in lymphocytic lymphoma. Nitrosourea derivatives appear to be only moderately effective compared to other agents. There are a number of active combinations presently on study, but none can yet be recognized as the treatment of choice for all histologic types. Available data show that cyclic combination chemotherapy produces a higher percentage of complete remissions compared to single agents. This also applies to median duration of response and median survival time. Treatment of non-Hodgkin's lymphomas has improved during the past few years primarily because of intensive cyclic combination chemotherapy and new effective agents. There is a need for an entirely new approach which should be based on standardized histopathologic and staging classification as well as on controlled studies.

AB - Single agent and combination chemotherapy of non-Hodgkin's lymphomas are reviewed. Cyclophosphamide, vincristine and adriamycin appear to be the most effective single agents. Bleomycin is also effective and particularly indicated either in combination or in patients with active disease and concomitant myelosuppression. Corticosteroids are mostly active in lymphocytic lymphoma. Nitrosourea derivatives appear to be only moderately effective compared to other agents. There are a number of active combinations presently on study, but none can yet be recognized as the treatment of choice for all histologic types. Available data show that cyclic combination chemotherapy produces a higher percentage of complete remissions compared to single agents. This also applies to median duration of response and median survival time. Treatment of non-Hodgkin's lymphomas has improved during the past few years primarily because of intensive cyclic combination chemotherapy and new effective agents. There is a need for an entirely new approach which should be based on standardized histopathologic and staging classification as well as on controlled studies.

UR - http://www.scopus.com/inward/record.url?scp=0016183622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016183622&partnerID=8YFLogxK

U2 - 10.1016/S0305-7372(74)80001-0

DO - 10.1016/S0305-7372(74)80001-0

M3 - Article

VL - 1

SP - 167

EP - 181

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 3

ER -